METHODS: In this population-based study, incidence rates (IR) per 100 person-years-at-risk (PYAR) for men and women ≥45 years registered with an UK primary care practice between 2010 and 2021 were estimated. Incidence rate ratios (IRR) with 95 % confidence intervals (CIs) of CMHD were estimated using men as a reference. We measured first prescriptions for psychotropic medications received within 12 months after CMHD. For selective serotonin reuptake inhibitors (SSRIs) /selective norepinephrine reuptake inhibitors (SNRIs), we measured the IR of prescribing per 100 PYAR, by 10-year bands. Proportion of SSRIs/SNRIs prescribing was estimated per 100 persons.
RESULTS: Rates of anxiety and depressive disorders were 1.68 and 1.69 per 100 PYAR in women aged 45-54 years-old compared to 0.91 and 1.20 per 100 PYAR in men, with IRR of 1.84 (95 % CI 1.72-1.97) and 1.44 (1.35-1.53) respectively. SSRIs/SNRIs were the most prescribed medication; in 2021, IRs for SSRIs/SNRIs were 13.4 per 100 PYAR in both sexes. In 2021, the proportion of SSRIs/SNRIs prescribing was 50.67 per 100 women and 41.91 per 100 men.
CONCLUSIONS: MT is assumed based on women\'s age as menopause onset is rarely recorded in primary care databases.
CONCLUSIONS: Women ≥45 years experienced more CMHD compared to men, especially 45-54 years-olds, which coincides with MT. The proportion of SSRIs/SNRIs prescribing was higher in women.
方法:在这项基于人群的研究中,我们估算了2010年至2021年在英国初级保健机构登记的≥45岁男性和女性每100人年高危人群(PYAR)的发病率(IR).以男性为参考,估计CMHD的发生率比率(IRR)和95%置信区间(CIs)。我们测量了CMHD后12个月内接受的第一批精神药物处方。对于选择性5-羟色胺再摄取抑制剂(SSRIs)/选择性去甲肾上腺素再摄取抑制剂(SNRIs),我们测量了每100PYAR的处方IR,十年乐队SSRIs/SNRIs处方的比例估计为每100人。
结果:45-54岁女性的焦虑和抑郁障碍发生率为1.68和1.69/100PYAR,而男性为0.91和1.20/100PYAR。IRR分别为1.84(95%CI1.72-1.97)和1.44(1.35-1.53)。SSRIs/SNRIs是处方最多的药物;2021年,男女SSRIs/SNRIs的IRs为每100PYAR13.4。2021年,SSRIs/SNRIs处方的比例为每100名女性50.67人,每100名男性41.91人。
结论:MT是基于女性的年龄假设的,因为初级保健数据库中很少记录更年期的发作。
结论:与男性相比,≥45岁的女性经历了更多的CMHD,尤其是45-54岁的年轻人,这与MT相吻合。女性处方SSRIs/SNRIs的比例较高。